NMD4C steering committee member Stacey Lintern appointed CEO of Muscular Dystrophy Canada

We are happy to congratulate our steering committee member Stacey Lintern for her recent appointment as CEO of our partner organization Muscular Dystrophy Canada (MDC)!

Read MDC’s statement below:

The Board of Muscular Dystrophy Canada is pleased to announce the appointment of Stacey Lintern as Chief Executive Officer, effective September 9, 2020.

Stacey has been with Muscular Dystrophy Canada since 2012 and has been acting as the interim-CEO since mid-April, 2020. She has extensive experience in the not-for-profit sector and has worked as a senior manager in large health organizations and in government, where she managed organizational development, strategic planning, stakeholder relations, partnerships, and mission delivery. During her time with MDC, Stacey has held a range of senior positions. Before taking on the role of CEO, she was the Chief Operating Officer.

Stacey has built an incredible reputation over the last 20+ years working in this field. She has worked with many non-profit boards, helping to build their capacity to thrive and increase their impact.

Stacey knows our clients, their families and the caregiver community. She has developed successful and enduring relationships with many of our key stakeholders and partners. We believe that Stacey’s leadership, skills, talent, her passion for MDC and for the work we all do will help drive the organization forward as we navigate our way through many of the challenges related to COVID-19 and beyond.

Through her visionary leadership and strong commitment to achieving organizational goals, Stacey maintains a focus on maximizing the potential of MDC’s clients, staff and our diverse group of stakeholders and supporters. In both words and actions, Stacey exhibits a clear dedication to building a culture of empowerment, respect, trust, accountability and innovation.

“I am extremely honoured to serve as MDC’s CEO. I am committed and excited to support the neuromuscular community, face the many challenges, lead and work with our dedicated staff, volunteers, donors, partners and many supporters to deliver our critical mission objectives. I know that people are counting on us to make a difference, and we can”.

Stacey started her career in the Nursing field and made the transition to the disability and health sectors with a focus on independent living, community integration and patients directing their care. Stacey is a graduate of York University Executive Leadership Program and the University of Toronto Post Graduate Executive Advanced Business Management Program. And, she looks forward to continuing her education as she enters into the Canadian Health Executive Program offer through the University of British Columbia.

The Board of MDC is committed to doing everything we can to continue to support our clients and their families through this time, and to advocate on their behalf. We are working closely with and fully support Stacey and the entire MDC team in their efforts to ensure the organization remains strong and viable.

stacey

Read next...

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.

Website - SBMA published on CMAJ.png

New Best Practice Recommendations for SBMA Care in Canada

Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!

2025 NMD4C ANNUAL MEETING

Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting

On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.

2025 Clinical Summer School

NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders

On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.

2026 Neuromuscular Postdoc Research Fellowship Competition

2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!

Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)

Clinical Fellowship Awardees

Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients

We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.